Living prosthetic breast for promoting tissue regeneration and inhibiting tumor recurrence

Abstract

Abstract Developing a living prosthetic breast to inhibit potential breast cancer recurrence and simultaneously promote breast reconstruction would be a promising strategy for clinical treatment of breast cancer after mastectomy. Here, a living prosthetic breast in the form of injectable gelatin methacryloyl microspheres is prepared, where they encapsulated zeolitic imidazolate framework (ZIF) nanoparticles loaded with small molecules urolithin C (Uro‐C) and adipose‐derived stem cells (ADSCs). Taking advantage of the acidic tumor microenvironment, the ZIF triggered a pH‐sensitive drug release in situ so that Uro‐C can induce tumor cell apoptosis via reactive oxygen species (ROS) generation. Meanwhile, the ADSCs proliferate in situ to promote tissue regeneration. Using such a design, our data showed that the ADSCs maintained viable and proliferate under the inhibitory effect of Uro‐C in vitro. Through ROS generation, Uro‐C also activated a suppressive tumor microenvironment in mice by both re‐polarizing M2 macrophages to M1 macrophages for elevated inflammatory responses, and increasing the ratio between CD8 and CD4 T cells for tumor recurrence inhibition, significantly promoting new adipose tissue formation. Altogether, our results demonstrate that the prepared living prosthetic breast with bifunctional properties can be a promising candidate in clinic involving tumor treatment and tissue engineering in synergy.

Keywords

• Breast cancer treatment
• Cell‐laden microspheres
• Drug delivery
• Living prosthetic breast
• Regenerative medicine